Genscript Biotech Corporation
金斯瑞生物科技股份有限公司 *
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1548)

OVERSEAS REGULATORY ANNOUNCEMENT UNAUDITED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED 31 MARCH 2023 BY A LISTED SUBSIDIARY — LEGEND BIOTECH CORPORATION

This announcement is made by the board of directors (the "**Board**") of Genscript Biotech Corporation (the "**Company**") pursuant to Rules 13.09 and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Legend Biotech Corporation ("**Legend**"), a non-wholly owned subsidiary of the Company, whose shares are listed by way of American Depositary Shares on the Nasdaq Global Select Market in the United States, has filed a Form 6-K with the United States Securities and Exchange Commission (the "**SEC**") in relation to the unaudited financial results of Legend for the first quarter ended 31 March 2023 and recent business highlights ("**Results**") and its updated pipeline of product candidates (the "**Pipeline**"). For details, please refer to the attached Results and Pipeline. The attachment is the full Form 6-K as published on the SEC's website available at https://www.sec.gov/Archives/edgar/data/1801198/000115752323000881/0001157523-23-000881-index.html.

This announcement has been issued in the English language with a separate Chinese language translation. If there is any inconsistency or ambiguity between the English version and the Chinese version, the English version shall prevail.

By Order of the Board
Genscript Biotech Corporation
MENG Jiange
Chairman and Executive Director

Hong Kong, 18 May 2023

As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan and Dr. Wang Xuehai

* *For identification purposes only*

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

Date of Report: May 18, 2023

Commission File Number: 001-39307

Legend Biotech Corporation
(Exact Name of Registrant as Specified in its Charter)

2101 Cottontail Lane
Somerset, New Jersey 08873
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Legend Biotech Reports First Quarter 2023 Financial Results and Recent Highlights

On May 18, 2023, Legend Biotech Corporation ("Legend Biotech") issued a press release regarding its unaudited financial results for the three months ended March 31, 2023 and recent business highlights, which is attached to this Form 6-K as Exhibit 99.1. In addition, Legend Biotech is updating its pipeline of product candidates, as set forth in Exhibit 99.2 to this Form 6-K.

This report on Form 6-K, including Exhibits 99.1 and 99.2, is hereby incorporated by reference in the registration statements of Legend Biotech on Form F-3 (Nos. 333-257609 and 333-257625) and Form S-8 (No. 333-239478), to the extent not superseded by documents or reports subsequently filed.

Cautionary Note Regarding Forward-Looking Statements

Statements in this Report on Form 6-K about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Legend Biotech's strategies and objectives; statements relating to CARVYKTI®, including Legend Biotech's expectations for CARVYKTI®, such as Legend Biotech's manufacturing and commercialization expectations for CARVYKTI® and the potential effect of treatment with CARVYKTI®; the anticipated timing of, and ability to progress, clinical trials; the ability to generate, analyze and present data from clinical trials; expected results of clinical trials; the potential benefits of Legend Biotech's product candidates; and Legend Biotech's ability to fund its planned initiatives and operations through the end of 2025. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech's expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by our third party partners; uncertainties arising from challenges to Legend Biotech's patent or other proprietary intellectual property protection, including the uncertainties involved in the U.S. litigation process; competition in general; government, industry, and general product pricing and other political pressures; the duration and severity of the COVID-19 pandemic and governmental and regulatory measures implemented in response to the evolving situation; as well as the other factors discussed in the "Risk Factors" section of Legend Biotech's Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 30, 2023. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this Report on Form 6-K as anticipated, believed, estimated or expected. Any forward-looking statements contained in this Report on Form 6-K speak only as of the date of this Report on Form 6-K. Legend Biotech specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

EXHIBIT INDEX

Exhibit	Title
99.1	Press Release, dated May 18, 2023
99.2	Pipeline

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

LEGEND BIOTECH CORPORATION

Date: May 18, 2023

By: /s/ Ying Huang
Name: Ying Huang, Ph.D.
Title: Chief Executive Officer

Legend Biotech Reports First Quarter 2023 Results and Recent Highlights

- *New and updated data from the CARTITUDE Clinical Development Program and LEGEND-2 study evaluating ciltacabtagene autoleucel (cilta-cel) will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association's (EHA) 2023 Hybrid Congress*
- *$350 million in gross proceeds raised in a registered direct offering*
- *$212 million in gross proceeds raised from private placements*
- *Gross proceeds of $200 million received from the exercise of warrant issued in May 2021*
- *Strategic advisory board established with the appointments of John Maraganore, Ph.D., former CEO of Alnylam Pharmaceuticals and Michel Vounatsos, former CEO of Biogen Inc. as advisors*
- *Mythili Koneru, M.D., Ph.D. appointed as Company's Chief Medical Officer*

SOMERSET, N.J.— May 18, 2023— Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today reported its first quarter 2023 unaudited financial results.

"We are extremely pleased to announce that we have recently raised $762 million in funding. With this substantial capital infusion, we are poised to embark on a critical chapter in our company's growth to advance CARVYKTI® toward its full potential, and we look forward to presenting the latest data from our CARTITUDE clinical development programs at ASCO and EHA this June," said Ying Huang, Chief Executive Officer of Legend Biotech. Dr. Huang continued, "We would like to extend our deepest gratitude to our investors for their overwhelming support and confidence in our company's mission and remain committed to creating long-term value for all of our stakeholders."

Financial Results for Quarter Ended March 31, 2023

Cash and Cash Equivalents, Time Deposits, and Short-Term Investments
As of March 31, 2023, prior to giving effect to the registered direct offering, private placements or warrant exercise noted above, Legend Biotech had approximately $854 million of cash and cash equivalents, time deposits, and short-term investments.

Revenue
Total revenue for the three months ended March 31, 2023 was $36.3 million compared to $50.0 million for the three months ended March 31, 2022. Collaboration revenue recognized in the first quarter of 2023 was from CARVYKTI® sales primarily in the U.S. License revenue recognized in first quarter of 2022 was due to the

achievement of commercial milestone for FDA approval in the U.S. in connection with the license and collaboration agreement (the "Janssen Agreement") with Janssen Biotech, Inc. ("Janssen").

Collaboration cost of revenue

Collaboration cost of revenue for the three months ended March 31, 2023 was $35.6 million. Legend Biotech did not have any collaboration cost of revenue in the three months ended March 31, 2022. The $35.6 million is a combination of Legend's portion of collaboration cost of sales in connection with collaboration revenue under the Janssen Agreement along with expenditures to support the manufacturing capacity expansion which cannot be capitalized.

Research and Development Expenses

Research and development expenses for the three months ended March 31, 2023 were $84.9 million compared to $81.5 million for the three months ended March 31, 2022. This increase of $3.4 million was primarily due to higher patient enrollment for Phase 3 clinical trials for cilta-cel in the first quarter of 2023.

Administrative Expenses

Administrative expenses for the three months ended March 31, 2023 were $22.2 million compared to $12.7 million for the three months ended March 31, 2022. The increase of $9.5 million was primarily due to continued investment in building global information technology infrastructure along with non-recurring financial and legal fees related to Legend Biotech's restatement of its historical financial statements as reported by Legend Biotech in February 2023.

Selling and Distribution Expenses

Selling and distribution expenses for the three months ended March 31, 2023 were $18 million compared to $21.3 million for the year three months ended March 31, 2022. This decrease of $3.3 million was primarily due to non-recurring launch expenses incurred in the first quarter of 2022 to support the commercialization in the U.S market.

Other Income and Gains

Other income and gains for the three months ended March 31, 2023 were $8.2 million compared to $1.0 million for the three months ended March 31, 2022. The increase of $7.2 million was primarily due to increase in interest income and gain on investments.

Other Expenses

Other expenses for the three months ended March 31, 2023 were $10.7 million compared to $1.5 million for the three months ended March 31, 2022. The increase was primarily due to unrealized foreign currency exchange loss in the quarter.

Finance Costs

Finance costs for the three months ended March 31, 2023 were $5.1 million compared to $1 million for the three months ended March 31, 2022. The increase was primarily due to interest on advance funding, which is interest-bearing borrowings funded by Janssen under the Janssen Agreement and constituted by principal and applicable interests upon such principal.

Fair Value Gain of Warrant Liability

Fair value gain of warrant liability for the three months ended March 31, 2023 was $20 million caused by changes in the fair value of a warrant that Legend Biotech issued to an institutional investor through a private placement transaction in May 2021 with an initial fair value of $81.7 million at the issuance date. The warrant was assessed as a financial liability with a fair value of $47.0 million as of March 31, 2023. On May 12, 2023, Legend Biotech announced that the warrant had been exercised in full.

Loss for the Period

For the three months ended March 31, 2023, net loss was $112.1 million, or $0.34 per share, compared to a net loss of $32.3 million, or $0.10 per share, for the three months ended March 31, 2022.

About Legend Biotech

Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.

Learn more at www.legendbiotech.com and follow us on Twitter and LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Legend Biotech's strategies and objectives; statements relating to CARVYKTI®, including Legend Biotech's expectations for CARVYKTI®, such as Legend Biotech's manufacturing and commercialization expectations for CARVYKTI® and the potential effect of treatment with CARVYKTI®; statements about submissions for CARVYKTI® and other product candidates to, and the progress of such submissions with, the U.S. Food and Drug Administration (FDA) and other regulatory authorities; the anticipated timing of, and ability to progress, clinical trials; the ability to generate, analyze and present data from clinical trials; expected results of clinical trials; and the potential benefits of Legend Biotech's product candidates. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech's expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by our third party partners; uncertainties arising from challenges to Legend Biotech's patent or other proprietary intellectual property protection, including the uncertainties involved in the U.S. litigation process; competition in general; government, industry, and general product pricing and other political pressures; the duration and severity of the COVID-19

pandemic and governmental and regulatory measures implemented in response to the evolving situation; as well as the other factors discussed in the "Risk Factors" section of Legend Biotech's Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 29, 2023. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this press release as anticipated, believed, estimated or expected. Any forward-looking statements contained in this press release speak only as of the date of this press release. Legend Biotech specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

INVESTOR CONTACTS:
Joanne Choi, Senior Manager, Investor Relations, Legend Biotech
joanne.choi@legendbiotech.com

Crystal Chen, Manager, Investor Relations, Legend Biotech
crystal.chen@legendbiotech.cn

PRESS CONTACT:
Tina Carter, Corporate Communications Lead, Legend Biotech
tina.carter@legendbiotech.com
(908) 331-5025

LEGEND BIOTECH CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS

	Three months ended March 31,	Three months ended March 31,
	US$'000, except per share data	US$'000, except per share data
	(Unaudited)	(Unaudited)
REVENUE		
License revenue	—	50,000
Collaboration revenue	36,280	—
Other revenue	56	40
Total revenue	36,336	50,040
Collaboration cost of revenue	(35,613)	—
Other income and gains	8,199	1,012
Research and development expenses	(84,889)	(81,548)
Administrative expenses	(22,205)	(12,657)
Selling and distribution expenses	(17,954)	(21,302)
Other expenses	(10,734)	(1,527)
Fair value gain of warrant liability	20,000	34,900
Finance costs	(5,113)	(1,044)
LOSS BEFORE TAX	(111,973)	(32,126)
Income tax (expense)/credit	(128)	(163)
LOSS FOR THE PERIOD	(112,101)	(32,289)
Attributable to:		
Ordinary equity holders of the parent	(112,101)	(32,289)
LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS		
Basic	(0.34)	(0.10)
Diluted	(0.34)	(0.10)
ORDINARY SHARES USED IN LOSS PER SHARE COMPUTATION		
Basic	330,497,072	308,699,034
Diluted	330,497,072	308,699,034

LEGEND BIOTECH CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

	March 31, 2023	December 31, 2022
	US$'000 (Unaudited)	US$'000 (Audited)
NON-CURRENT ASSETS		
Property, plant and equipment	110,045	105,168
Advance payments for property, plant and equipment	2,193	914
Right-of-use assets	80,459	55,590
Time deposits	4,366	—
Intangible assets	2,289	3,409
Collaboration prepaid leases	93,548	65,276
Other non-current assets	1,062	1,487
Total non-current assets	293,962	231,844
CURRENT ASSETS		
Collaboration inventories	12,176	10,354
Trade receivables	56	90
Prepayments, other receivables and other assets	51,761	61,755
Financial assets at fair value through profit or loss	185,705	185,603
Pledged deposits	1,283	1,270
Time deposits	4,366	54,016
Cash and cash equivalents	660,050	786,031
Total current assets	915,397	1,099,11
Total assets	1,209,35	1,330,96
CURRENT LIABILITIES		
Trade payables	29,811	32,893
Other payables and accruals	146,378	184,109
Government grants	457	451
Lease liabilities	4,595	3,563
Tax payable	9,940	9,772
Warrant liability	47,000	67,000
Total current liabilities	238,181	297,788
NON-CURRENT LIABILITIES		
Collaboration interest-bearing advanced funding	265,864	260,932
Lease liabilities long term	44,302	20,039
Government grants	7,631	7,659
Other non-current liabilities	224	233
Total non-current liabilities	318,021	288,863
Total liabilities	556,202	586,651
EQUITY		
Share capital	33	33
Reserves	653,124	744,279
Total ordinary shareholders' equity	653,157	744,312
Total equity	653,157	744,312
Total liabilities and equity	1,209,35	1,330,96

LEGEND BIOTECH CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW

	Three months ended March 31, 2023	Three months ended March 31, 2022
	US$'000 (Unaudited)	US$'000 (Unaudited)
LOSS BEFORE TAX	(111,973)	(32,126)
CASH FLOWS USED IN OPERATING ACTIVITIES	(141,053)	(78,687)
CASH FLOWS USED IN INVESTING ACTIVITIES	17,930	(232,500)
CASH FLOWS FROM FINANCING ACTIVITIES	(286)	25
NET DECREASE IN CASH AND CASH EQUIVALENTS	(123,409)	(311,162)
Effect of foreign exchange rate changes, net	(2,572)	10
Cash and cash equivalents at beginning of the period	786,031	688,938
CASH AND CASH EQUIVALENTS AT END OF THE PERIOD	660,050	377,786
ANALYSIS OF BALANCES OF CASH AND CASH		
Cash and bank balances	670,065	667,465
Less: Pledged deposits	1,283	1,448
Time deposits	8,732	288,231
Cash and cash equivalents as stated in the statement of financial position	660,050	377,786
Cash and cash equivalents as stated in the statement of cash flows	660,050	377,786

Global | US | China

Preclinical	Phase 1		Phase 2	Phase 3
SCLC‡ **(DLL3)** Autologous	**GASTRIC, ESOPHAGEAL & PANCREATIC†** **(CLAUDIN 18.2)** Autologous NCT04467853	**RRMM (BCMA)** **LEGEND-2†** Autologous NCT03090659	**RRMM (BCMA)*** **CARTIFAN-1** Autologous NCT03758417	**RRMM (BCMA)*** **1-3 Prior Lines** **CARTITUDE-4** Autologous NCT04181827
NSCLC **(GPC3)** Autologous	**GASTRIC, ESOPHAGEAL & PANCREATIC‡** **(CLAUDIN 18.2)** Autologous NCT05539430	**NHL† /ALL†** **(CD19 X CD20 X CD22)†** Autologous NCT05318963 NCT05292898	**RRMM (BCMA)*** **CARTITUDE-1** Autologous NCT03548207	**NDMM (BCMA)*** **Transplant Not Intended** **CARTITUDE-5** Autologous NCT04923893
COLORECTAL **(GCC)** Autologous	**MM†** **(BCMA)** Allogeneic – CAR-NK NCT05498545	**HCC†** **(GPC3)** Autologous NCT05352542	**MM (BCMA)*** **CARTITUDE-2** Autologous NCT04133636	**NDMM (BCMA)*** **Transplant Eligible** **CARTITUDE-6** Autologous NCT05257083
	MM† **(BCMA)** Allogeneic – CAR-γδ T NCT05376345	**AML** **(CLL1/CD33)** Allogeneic – CAR-γδ T NCT05654779		

The safety and efficacy of the agents and/or uses under investigation have not been established.
There is no assurance that the agents will receive health authority approval or become commercially available in any country for the uses being investigated. Additionally, as some programs are still confidential, certain candidates may not be included in this list.

*In collaboration with Janssen, Pharmaceutical Companies of Johnson & Johnson.
†Phase 1 IIT in China.
‡IND applications have been cleared by the U.S. FDA.

ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BCMA, B-cell maturation antigen; DLL3, delta-like ligand 3; GPC3, glypican-3; GCC, guanylyl cyclase C; HCC, hepatocellular carcinoma; IIT, investigator-initiated trial; MM, multiple myeloma; ND, newly diagnosed; NHL, non-Hodgkin lymphoma; NSCLC, non small cell lung cancer; RRMM, relapsed or refractory multiple myeloma; SCLC, small cell lung cancer.